S 3536
Latest Information Update: 08 Apr 2005
Price :
$50 *
At a glance
- Originator Shionogi
- Class
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 31 Dec 2004 Discontinued - Phase-I for Osteoarthritis in Europe (PO)
- 17 May 2004 Phase-I clinical trials in Osteoarthritis in Europe (PO)
- 10 Nov 2003 Phase-I clinical trials in Osteoarthritis in USA (PO)